Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2022, with the report dated May 3, 2022. The filing serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
| Metric | Value |
|---|---|
| Issued Share Capital (as of April 29, 2022) | 5,388,880,497 Ordinary Shares (25 pence each) |
| Treasury Shares | 304,905,950 |
| Total Voting Rights | 5,083,974,547 |
Material Changes
The filing text does not provide a clear value for material changes versus a prior comparable period regarding financial performance. The document focuses on the static capital position as of April 29, 2022, to assist shareholders in calculating notification thresholds under FCA rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures beyond the regulatory context of shareholding notifications.
Important Facts for Investors
- Voting Rights Denominator: Investors should use 5,083,974,547 as the denominator to determine if they are required to notify their interest in GSK under FCA rules.
- Treasury Holdings: Approximately 304.9 million shares are held in Treasury and do not carry voting rights.
- Share Class: The capital consists entirely of Ordinary Shares with a nominal value of 25 pence each.
- Reporting Date: The capital figures are accurate as of April 29, 2022.